Authors: Cathay Davies, Robin Wilson, Elizabeth Appiah-Kusi, Michael Brammer, Jesus Perez, Robin Murray, Paul Allen, Matthijas Bossong, Philip McGuire and Sagnik Bhattacharyya Published in Schizophrenia Bulletin May 2020 Abstract Background There is currently a lack of effective pharmacological treatment for people at Clinical High Risk of Psychosis (CHR), who present with emotional dysregulation and…
Authors: Sy Atezaz Saeed, MD, MS, and Kathryn E. Clary, BA Published in Current Psychiatry June 2020 Introduction There has been increasing interest in the medicinal use of cannabidiol (CBD) for a wide variety of health conditions. CBD is one of more than 80 chemicals identified in the Cannabis sativa plant, otherwise known as…
Authors: Sanne J. van der Steur, Albert Batalla, Matthijs G. Bossong Published in Brain Sciences 12 February 2020 Abstract Increasing evidence indicates a relationship between cannabis use and psychosis risk. Specific factors, such as determinants of cannabis use or the genetic profile of cannabis users, appear to moderate this association. The present systematic review…
European Neuropsychopharmacology, 10 February 2020
—
Cannabis use induces a plethora of actions on the CNS via its active chemical ingredients, the so-called phytocannabinoids. These compounds have been frequently associated with the intoxicating properties of cannabis preparations. However, not all phytocannabinoids are psychot…
Schizophrenia Bulletin, November 2018
—
Background: Cannabis use in young people is common and associated with psychiatric disorders. However, the prospective link between cannabis use and bipolar disorder symptoms has rarely been investigated. The study hypothesis was that adolescent cannabis use is associated with…
American Journal of Psychiatry, April 2018
—
OBJECTIVE: The authors investigated the rates of conversion to schizophrenia and bipolar disorder after a substance-induced psychosis, as well as risk factors for conversion. METHOD: All patient information was extracted from the Danish Civil Registration System and the Psychi…
The British Journal of Psychiatry, April 2018
—
BACKGROUND: The association between cannabis use and the risk of psychosis has been studied extensively but the temporal order still remains controversial. Aims To examine the association between cannabis use in adolescence and the risk of psychosis after adjustment for prodro…
Schizophrenia Bulletin, 13 January 2018
—
A major factor associated with poor prognostic outcome after a first psychotic break is cannabis misuse, which is prevalent in schizophrenia and particularly common in individuals with recent-onset psychosis. Behavioral interventions aimed at reducing cannabis use have been un…
The Lancet Psychiatry, March 2015
—
BACKGROUND: The risk of individuals having adverse effects from drug use (eg, alcohol) generally depends on the frequency of use and potency of the drug used. We aimed to investigate how frequent use of skunk-like (high-potency) cannabis in south London affected the associatio…
Schizophrenia Research, January 2014
—
BACKGROUND: Cannabis is one of the most highly abused illicit drugs in the world. Several studies suggest a link between adolescent cannabis use and schizophrenia. An understanding of this link would have significant implications for legalization of cannabis and its medicinal…
The Journal of Clinical Psychiatry, April 2013
—
As more US states and other countries consider legalizing marijuana, clinicians need to know the possible effects of this drug. Research has shown a connection between marijuana use and an increased risk for schizophrenia in young people who are vulnerable to developing psycho…
Translational Psychiatry, 20 March 2012
—
Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an elevation of anandamide levels in cerebrospinal fluid inversely correlated to psychot…